What is a stock summary page? Click here for an overview.
Business Description
I-MAB
ISIN : US44975P1030
Share Class Description:
IMAB: ADRCompare
Compare
Traded in other countries / regions
IMAB.USA0VY.Germany Index Membership
China Concepts StockNASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China Index IPO Date
2020-01-17Description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 48.77 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -6.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -76.1 | |||||
| 3-Year Book Growth Rate | -37 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -33.52 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.57 | |||||
| 9-Day RSI | 49.98 | |||||
| 14-Day RSI | 46.37 | |||||
| 3-1 Month Momentum % | -2.22 | |||||
| 6-1 Month Momentum % | -17.76 | |||||
| 12-1 Month Momentum % | -52.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.99 | |||||
| Quick Ratio | 15.99 | |||||
| Cash Ratio | 15.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4 | |||||
| Shareholder Yield % | 2.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -5110.57 | |||||
| Net Margin % | -1903.58 | |||||
| FCF Margin % | -5673.45 | |||||
| ROE % | -26.82 | |||||
| ROA % | -21.86 | |||||
| ROIC % | -391.48 | |||||
| 3-Year ROIIC % | 185.75 | |||||
| ROC (Joel Greenblatt) % | -2082.73 | |||||
| ROCE % | -78.39 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 21.87 | |||||
| PB Ratio | 0.32 | |||||
| Price-to-Tangible-Book | 0.32 | |||||
| EV-to-EBIT | 0.54 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.54 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | -33.55 | |||||
| EV-to-Forward-Revenue | 0.23 | |||||
| EV-to-FCF | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 0.4 | |||||
| Price-to-Net-Cash | 0.41 | |||||
| Earnings Yield (Greenblatt) % | 185.19 | |||||
| FCF Yield % | -266.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
I-MAB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.273 | ||
| EPS (TTM) ($) | -0.76 | ||
| Beta | 1.12 | ||
| 3-Year Sharpe Ratio | -1.29 | ||
| 3-Year Sortino Ratio | -1.44 | ||
| Volatility % | 39.92 | ||
| 14-Day RSI | 46.37 | ||
| 14-Day ATR ($) | 0.053278 | ||
| 20-Day SMA ($) | 0.868683 | ||
| 12-1 Month Momentum % | -52.69 | ||
| 52-Week Range ($) | 0.76 - 2 | ||
| Shares Outstanding (Mil) | 81.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
I-MAB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
I-MAB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
I-MAB Frequently Asked Questions
What is I-MAB(IMAB)'s stock price today?
The current price of IMAB is $0.85. The 52 week high of IMAB is $2.00 and 52 week low is $0.76.
When is next earnings date of I-MAB(IMAB)?
The next earnings date of I-MAB(IMAB) is 2025-03-28 Est..
Does I-MAB(IMAB) pay dividends? If so, how much?
I-MAB(IMAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers